




	Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000 diversity library 
	New anti-Wolbachia chemotypes identified 
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One sentence summary: 
Screening of 10K compounds reveals new anti-Wolbachia chemotypes with potential to be developed into new drugs for two NTDs

H2:Abstract





The Wolbachia endosymbiont of filarial nematodes is a validated chemotherapeutic target for the treatment of lymphatic filariasis  ADDIN EN.CITE (1-7) and onchocerciasis  ADDIN EN.CITE (8-11). These debilitating neglected tropical diseases (NTDs) affect more than 150 million people and while control programs have made great strides in reducing prevalence in endemic countries  ADDIN EN.CITE (12, 13), progress towards elimination is hampered by the lack of a safe drug capable of killing adult worms  ADDIN EN.CITE (14, 15). Targeting the Wolbachia bacteria within filarial nematodes using antibiotics offers the desired macrofilaricidal activity, as the nematodes rely on their endosymbionts for their development, fecundity and survival  ADDIN EN.CITE (16). Furthermore, an anti-Wolbachia mode of action provides an excellent safety profile due to the protracted death of adult worms. Importantly such a mechanism has no effect on the Wolbachia-negative Loa loa parasites that can cause serious adverse events in some co-infected individuals treated with the standard anti-filarial drug ivermectin  ADDIN EN.CITE (17). Doxycycline has been proven effective as an anti-Wolbachia macrofilaricidal agent, but its long course of treatment (4-6 weeks) and contraindications in pregnancy and young children restricts its widespread use. The Anti-Wolbachia (A∙WOL) consortium was formed with the aim of finding a new anti-Wolbachia treatment with a shorter treatment duration (ideally less than seven days) and utility in pregnant women and children  ADDIN EN.CITE (18, 19).




	In order to optimize our existing validated screening assay  ADDIN EN.CITE (20) to increase throughput and capacity we made a number of adaptations that are detailed in the Supplementary Materials and Methods section. Briefly, all aspects of the screening workflow were scrutinized in terms of scalability by conducting pilot experiments using a small selection of BioFocus compound plates. The main improvements made were to the cell toxicity readout and the qPCR reagents, both of which reduced the screening time without affecting assay robustness. All amendments to the published protocol were validated using analysis of Z and Z′ statistical parameters and the subsequent primary screening of the library was completed in less than 1 year, an order of magnitude increase in our screening efficiency. 

Hits from primary screen
10,000 compounds from the BioFocus SoftFocus® libraries were screened against Wolbachia using the validated A∙WOL cell-based assay (Fig. 1). We incubated C6/36 (wAlbB) cells with compounds for nine days and performed qPCR on a Wolbachia single copy gene to analyze reductions in Wolbachia load. Doxycycline and vehicle (dimethyl sulfoxide, DMSO) were used as internal controls on each plate and direct cellular toxicity was assessed through the scoring of confluence using microscopy (Fig. 1). Hits were defined as those compounds that reduced the Wolbachia 16S copy number by 1 log or greater (log drop ≥ 1), without evidence of cytotoxicity to the A. albopictus cell line (a reduction in cell confluence of greater than 50%, as scored by microscopy). These stringent criteria were implemented in order to best optimize our ability to triage hits for follow-up given the size of the library and the throughput of our assay. Initial screening using a concentration of 2.5 µg/ml resulted in 174 primary hits (Fig. 2). Overall, the proportion of compounds producing direct toxicity to the cell line was 3.6%. Hits were re-screened at the same concentration, resulting in 112 re-confirmed hits (confirmation rate of 64%). 

Hit validation
	Of the 112 confirmed hits, 71 were available to buy as dry stocks and to be used in the validation process. As the original compound plates were provided as 10 mg/ml stocks, the final molar concentrations used in the primary screen fell within the range of 3.97 – 14.75 µM, with a mean of 6.65 µM and median of 6.68 µM. We conducted the validation testing using a standard concentration of 5 µM on two separate occasions. Toxicity was quantified on replicate plates using the CellTiter-Glo® assay. Hits were confirmed as those compounds that reduced the Wolbachia 16S copy number by 0.5 log or greater while maintaining a CellTiter-Glo® readout 70% or greater than the vehicle-treated control wells. In this way, 50 hits were identified and progressed into chemoinformatic analysis (Fig. 2). 

Chemoinformatic analysis
Chemoinformatic techniques can assist the drug discovery process by viewing, organizing and understanding relationships between measured biological data and molecular properties (30) in order to make quicker more accurate decisions. Using such chemoinformatics techniques, the 50 validated hits were profiled using the parameters listed in table S1, in order to identify the optimal chemotypes to enter a hit-to-lead phase. An ideal chemotype chosen for hit-to-lead development would be potent, display some initial structural-activity relationship (SAR) and ideally be lead/drug-like in pharmacokinetic, physiochemical and structural parameters. Full details of the filtering procedure are included in Supplementary Materials and Methods. 

Cluster analysis
Cluster analysis on the 50 hit compounds using molecular fingerprints (31) and their representation within chemical space, using principal component analysis (PCA) (32), revealed 6 main clusters with the other compounds being identified as singletons (Fig. 3). This clustering in chemical space was confirmed by inspection of the maximal common substructure of the clustered hits. 
Following approaches from the analysis performed on the outputs from the antimalarial high throughput screening performed by GlaxoSmithKline  ADDIN EN.CITE (33), we have used a procedure in order to assign a “selection score” to each compound, with the maximum score being 30. We wished to identify the best compounds and series, and to this end we focused on compound potency, lipophilicity, number of compounds in the cluster and molecular weight (please see Supplementary Materials and Methods for how the scores were assigned to each compound’s properties). This analysis revealed the six clusters identified all contained multiple compounds above our score threshold of 15 (Fig. 3).
The chemically distinct clusters displayed an initial structure activity relationship (i.e. they were not singletons), had µM to nM potency and acceptable lipophilicity with low molecular weights. The six hit series are summarized in Table 1 and include Thienopyrimidines (Series 1), Imidazo[4,5-c]pyridines (Series 2), Oxazepinones (Series 3), Imidazo[1,2-a]pyridines (Series 4), Pyrrolopyridines (Series 5) and Oxazole imidazolidinones (Series 6). Pareto analysis was performed to identify compound clusters with the best overall profile (34), considering the compounds’ potency, in silico toxicity and ADME properties. Pareto optimization allows simultaneous optimization of many properties (e.g. biological and physiochemical) through multi-parameter optimization (35). This approach allows trade-offs between sometimes competing objectives to be made, resulting in better compound profile overall. This approach is in contrast to historical drug discovery which focused on potency and led to many late-stage failures due to poor ADMET and/or physiochemical properties (36). Our analysis ranked all six series equally highly giving us confidence in the quality of the hit series for subsequent lead optimization (Supplementary Materials and Methods).
During the screening and analysis of this compound set, we were in the process of developing a High Content Imaging (Operetta, Perkin Elmer) assay  ADDIN EN.CITE (37). This assay enables dose response studies to be conducted and EC50 values to be estimated (data not obtainable using the qPCR technique). We used this Operetta-based assay to titrate the activity of selected hits and generate EC50 values. The EC50 range produced by the six hit chemotypes was 112 - 5681 nM (Table 2). At the same time, some of the selected hits were also assessed for their DMPK properties, including lipophilicity, aqueous solubility and metabolic stability in vitro. 
In the Thienopyrimidine series (Series 1), representative compound 1 has good potency, low LogD and a molecular weight of 358. The metabolic stability is poor but it was considered that this could be rectified by manipulation of metabolically susceptible groups within the starting point (dimethoxy ring system and benzylic linker). An additional attractive feature of this template is the modular nature of the chemistry for template syntheses, where simple SNAr reactions of 2,4-dichloro thienopyridine with suitable aromatic and aliphatic amines can be used to provide an array of diversely functionalized analogues.   
The Imidazo[4,5-c]pyridine series representative compound 2 had all around excellent physicochemical properties, metabolic stability and acceptable solubility. With the lowest molecular weight of the entire series, this molecule looks attractive for hit to lead optimisation focused on potency. Chemistry for the synthesis of analogues in this series is straightforward allowing manipulation of the 2- and 4- positions of the imidazo[4,5-c]pyridine core. In the Oxazepinone series, representative example 3 has good potency and physicochemical properties. Metabolic stability appears to be the key parameter for optimisation in this hit series and although the logD was measured at 2.8, overall solubility of this representative was poor (2 µM).
The most potent hit 4, an imidazo[1,2-a]pyridine, has a selection score of 26 and as seen for series representative 3 has weak metabolic stability. Improving metabolic stability will be the primary hit optimisation challenge for this series. In silico prediction of metabolic weak points in this hit compound identified the A- and D-rings and the benzylic linkers, so medicinal chemistry focused on mitigation of oxidative attack at these positions should be considered. In the remaining two hit series, whilst the pyrrolopyridine analogue 5 and oxazole imidazolidinone 6 had similar selection scores, series 5 was considered to be superior based on microsomal stability, measured solubility and low logD. As for the other series, modular chemistry elaboration of 5 is possible through SNAr reactions (of an appropriate 6-chloro analogue) to diversify the left hand side of hit molecule (6-position of the pyrrolopyridine core) as well as Suzuki chemistry for elaboration of the right hand side (2-position of the pyrrolopyridine core).

Hit to lead
Given the potency, synthetic tractability of Series 1 and the identification of the metabolic weak-spots, we initiated medicinal chemistry focused on the optimization of the DMPK properties (whilst maintaining or improving the anti-Wolbachia activity), in order to establish early leads for further development. On inspection of molecule 1, the electron rich nature of the dimethoxy aromatic ring, benzylic linker and 6-position of the thieno[3,2-d]pyrimidine-2,4-diamine were considered as potential points of P450 mediated oxidative metabolism. In addition to addressing metabolic stability, the lipophilicity and the molecular weight of this hit needed to be reduced in the hit to lead optimisation phase. Through iterative rounds of medicinal chemistry optimisation, we were able to show that by incorporating a strong electron withdrawing group in the 4-position of benzylic side-chain, we could significantly improve the anti-Wolbachia activity and metabolic stability. AWB124 was established as an early lead in the Thienopyrimidine series, with relatively low molecular weight, excellent potency, significantly improved DMPK properties and good safety window (Figure 4a). Further optimisation was focused on the trifluorophenyl ring side-chain of AWB124 and modification/truncation of the side-chain at the 2-position of the thienopyrimidine ring. We found that the 2-position N-isopropylamine is not essential for anti-Wolbachia activity and by conversion of the trifluorophenyl ring into the corresponding pyridyl ring system, the resulting molecule AWG117 was obtained. AWG117 expressed nanomolar anti-Wolbachia activity, had significantly lower lipophilicity compared with AWB124 (logD 2.5 versus 4.5) and much improved microsomal stability and aqueous solubility. Cytotoxicity evaluation in THP-1 cells indicated low cytotoxicity with a very good in vitro therapeutic index. This lead compound is now primed for additional lead optimization towards a candidate molecule.

H2: Discussion 
Here we describe the first large scale diversity screen against Wolbachia, a validated target of the filarial nematodes responsible for the NTDs lymphatic filariasis and onchocerciasis. We identified and validated 50 hits that could be clustered into six unique chemotypes with the potential for onward drug development. This is the first diversity screen ever performed against these neglected tropical diseases and one that has already delivered chemical novelty and diversity into what is currently a relatively narrow and mechanistically restricted drug portfolio. 
The drug discovery landscape for helminth diseases in general has been moribund for a long time, with most drugs for nematode infections of humans coming via the much less neglected veterinary market (38). There is an urgent need for an effective macrofilaricide to treat lymphatic filariasis and onchocerciasis and proof of concept clinical trials  ADDIN EN.CITE (1-11) have demonstrated that targeting Wolbachia provides this action with an excellent safety profile. The success of the A∙WOL approach has been validated as compounds discovered as active in the primary cell-based screen  ADDIN EN.CITE (20) have progressed through the A∙WOL screening funnel and a selection (including minocycline, rifampicin and the tylosin analogue, TylAMac™) have either been tested in clinical trials  ADDIN EN.CITE (39, 40) or selected for clinical candidate development (Steven A. Ward and Mark J. Taylor, personal communication). These compounds, repurposed anti-infective compounds, were sourced either from currently registered drugs on the market  ADDIN EN.CITE (20) or focused anti-infective libraries provided by pharmaceutical companies working on drug discovery programs for other pathogens  ADDIN EN.CITE (18, 19). The six structurally diverse chemotypes described here, therefore, represent the first foray into the unknown for A∙WOL drug discovery and, as such, offer exciting avenues of drug discovery research.
We have conducted the first large-scale diverse screening campaign against Wolbachia and validated 50 hits. A range of molecular properties were assessed to see if they correlated with delivering the one log drop in bacterial load desired of a hit compound. Analysis of molecular weight, ClogP, number of rotable bonds, number of hydrogen bond donors and acceptors and polar surface area for both the 9,950 inactive molecules and the 50 validated hits demonstrated that there is no clear trend for any of these molecular parameters in determining biological activity (fig. S1), thereby underscoring the benefits of examining diverse compound sets, with a broad range of molecular characteristics, against phenotype in the search for novel active compounds. 
Through chemoinformatic and cluster analysis six novel chemotypes were identified and assessed for various drug-related properties in silico. In addition, the most potent representatives determined by their measured EC50 values from each series were also assessed for their DMPK properties in vitro to evaluate their suitability for further development in the pipeline. We have demonstrated the tractability of one of the series by performing hit to lead optimization through the use of well-considered medicinal chemistry optimization strategies focused on enhancing metabolic stability. 
Although the top hits exemplified in Table 2 are not presented in any prior published literature, the core of 5 series (Series 1 – 5) belongs to a group of privileged pharmacophores that can target multiple biologically significant proteins which are relevant to a range of diseases. Thienopyrimidines (Series 1), imidazo[4,5-c]pyridines (Series 2), oxazepinones (Series 3), and pyrrolopyridines (Series 5) have been identified as inhibitors of a range of kinases  ADDIN EN.CITE (41-43) or modulators of various G-protein-coupled receptor (GPCR) proteins (44, 45) in the literature. Also, noticeably, thienopyrimidines (Series 1) have been reported to possess anti-malarial activities  ADDIN EN.CITE (46) and the oxazepinone core in Series 3 and the imidazo[1,2-a]pyridine core in Series 4 have appeared in the experimental drugs TAK-475 (squalene synthase inhibitor)  ADDIN EN.CITE (47) and Q203 (anti-tuberculosis agent)  ADDIN EN.CITE (48) respectively. However, the substituent patterns of the hit series identified in this campaign are distinctly different from any known molecules and we do not speculate that the protein targets of these anti-Wolbachia hits are related to any of those reported in the literature. Interestingly, oxazole imidazolidinones (Series 6) have very limited representation in the literature and can be considered as a completely novel chemotype for anti-infective activity.
All the available evidence indicates that the six novel chemotypes presented here have great potential to be developed further as anti-Wolbachia macrofilaricidal drugs for the treatment of lymphatic filariasis and onchocerciasis. The disclosure of these starting points should also enable other researchers active in this field to initiate their own medicinal chemistry optimization programs akin to those seen in the malaria and TB drug discovery fields  ADDIN EN.CITE (49, 50).

H2: Materials and Methods
Compounds
The collection of 10,000 compounds was provided by BioFocus. While the majority of compounds present were derived from the SoftFocus® libraries, some came from ThemePair™ (approx. 900), FieldFocus™ (approx. 1,000) and other (approx. 1,200) libraries. Overall, the collection encompassed kinase, ion channel, g-protein coupled receptor (GPCR), protease, protein-protein interaction, helix mimetic and nucleoside targeted libraries. Compounds were provided as DMSO stocks in 96-well compound storage plates at a concentration of 10 mg ml-1 and were stored at -20 °C until use. Dry stocks of hits were purchased from eMolecules, UK.
The synthesis of AWB124 and AWG117 are described in Supplementary Material and Methods and schemes S1 and S2, and the chemical characterization of both compounds is listed below. N2-isopropyl-N4-(2-(trifluoromethyl)benzyl)thieno[3,2-d]pyrimidine-2,4-diamine (AWB124): 1H NMR (400 MHz, CDCl3) δ (ppm) 7.68 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 5.3 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 5.3 Hz, 1H), 5.09 (br. s, 1H), 5.01 (d, J = 5.7 Hz, 2H), 4.79 (br. s, 1H), 4.20 – 4.06 (m, 1H), 1.18 (d, J = 6.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ (ppm) 160.87, 157.68, 137.84, 132.58, 131.40, 131.02, 130.02, 128.52, 127.75, 126.39, 124.96, 124.29, 106.24, 43.39, 41.42, 23.44. HRMS (Cl) C17H18N4F3S [M+H]+ 367.1196. Elemental (CHN) analysis: C17H17N4F3S requires C 55.73%, H 4.68%, N 15.29%, found C 55.64%, H 4.71%, N 15.33%.
N-((2-(trifluoromethyl)pyridin-3-yl)methyl)thieno[3,2-d]pyrimidin-4-amine (AWG117): 1H NMR (400 MHz, CDCl3) δ (ppm) 8.58 (s, 1H), 8.54 (d, J = 4.3 Hz, 1H), 7.99 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 5.4 Hz, 1H), 7.39 (dd, J = 10.1, 5.0 Hz, 2H), 5.41 (d, J = 5.2 Hz, 1H), 5.05 (d, J = 6.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ (ppm) 160.21, 159.91, 156.94, 154.91, 147.89, 138.88, 133.22, 131.37, 126.64, 125.53, 123.96, 115.26, 40.17. HRMS (ES+) C13H10F3N4S [M+H]+ 311.0575. Elemental (CHN) analysis: C13H9F3N4S requires C 50.32%, H 2.92%, N 18.06%, found C 50.41%, H 2.88%, N 18.10%.

In vitro Wolbachia cell-based screening assay
An Aedes albopictus cell line C6/36 (ATCC number CRL-1660) stably infected with Wolbachia pipientis wAlbB (C6/36 (wAlbB)) was routinely cultured in L15 Leibovitz medium containing 2 mM L-glutamine, 1% non-essential amino acids, 2% tryptose phosphate broth (Sigma-Aldrich, UK), and 5% heat-inactivated Foetal Calf Serum (Cambrex Bio Science, Walkersville, MD) at 26°C  ADDIN EN.CITE (51). A C6/36 (wAlbB) cell-based assay developed to screen drugs/compounds active against Wolbachia in vitro was used as previously described (52) with a few modifications. Briefly, 24 h prior to use, compound plates were thawed for at least two hours at room temperature, with rocking. Plates were centrifuged briefly (less than 30 seconds) to remove drops from the underside of the seal. Daughter plates were prepared from the master plates by transferring 10 μl into new plates and these were stored at 4 °C until the following day. C6/36 (wAlbB) cells, sub-cultured 24 h previously, were seeded at 10 000 cells per well in 96-well flat bottom sterile culture plates. Compounds from the daughter plates were diluted to the appropriate working concentration in culture medium, added to test wells and cells cultured in a total volume of 200 μl at 26 °C for 9 days. The final concentration of each compound used was 2.5 μg ml-1. Vehicle (DMSO)-treated medium and doxycycline at a concentration of 8 μM were used as negative and positive controls respectively and were included on each test plate. Compounds and controls were added in triplicate within plates (i.e. compounds from one plate were spread over three reciprocal cell plates, 18 compounds per plate). At the end of the screening assay, cytotoxicity was scored using microscopy (medium toxicity determined as approximately 50% or greater reduction in cell confluence in comparison to the DMSO control, high toxicity approximately 90% or greater reduction in confluence) and samples were collected by washing adherent cells once in sterile Dulbecco’s PBS (Sigma) and adding 150 μl Wizard® SV Lysis Buffer (Promega, UK) for genomic DNA (gDNA) extraction. 

DNA isolation and quantitative real-time PCR (qPCR)
Genomic DNA was extracted from C6/36 (wAlbB) cell lysates using the Wizard® SV 96 Genomic DNA Purification System (Promega) according to the manufacturer’s instructions and eluted in 100 μl water. Quantification of the ribosomal gene W. pipientis 16S, was performed as described previously  ADDIN EN.CITE (53) with modifications. Briefly, qPCR was carried out on a C1000™ thermocycler with a CFX384™ Real-Time System (Bio-Rad Laboratories Ltd, UK) under the following conditions: 95 °C for 3 min, 40 cycles of 95 °C for 10 s and 55 °C for 30 s. qPCR reactions were performed in 10 µl SsoFast™ EVAGreen® (Bio-Rad, UK) reactions containing 2 µl gDNA, 0.4 µM of each primer in 1x SsoFast™ EvaGreen® Supermix (BioRad, UK). Quantification was calculated by reference to a linear standard curve of log 10 diluted (5x106 - 5x100) full-length amplicons synthesised as single-stranded oligonucleotides (Sigma-Genosys, UK).

Quality control
The quality of individual assays was assessed by calculating Z and Z′ statistical parameters using the data generated by control wells (54). Data from assays that did not achieve Z′ factors of 0.4 or above were rejected and compounds were re-tested. A typical primary screening encompassing run is shown in Figure 1 and described in further detail in Supplementary Materials and Methods.

Hit confirmation
Compounds that reduced the Wolbachia 16S copy number by 1 log or greater were cherry-picked from the daughter plates and tested again in order to confirm the activity. Those that again achieved a log reduction in Wolbachia 16S copy numbers of 1 log or greater were considered confirmed hits.

Validation with dry stocks
Compounds were purchased from eMolecules and dissolved in DMSO before use. Working dilutions were prepared using appropriate molar concentrations and cell-based assays, with a qPCR readout, were conducted using the methods described above. Each compound was tested at a standard concentration of 5 µM. Duplicate plates were prepared and used to quantify cytotoxicity in a CellTiter-Glo® Luminescent Cell Viability Assay (Promega, UK), according to the manufacturer’s instructions. The level of cytotoxicity for each compound was determined by comparing the CellTiter-Glo® luminescence readout against the vehicle-treated control wells, with compounds that reduced the percentage luminescence by 30% or greater being classed as cytotoxic.
Selected hits were set up in dose response using a recently validated higher-throughput screen developed by A∙WOL  ADDIN EN.CITE (37). While utilizing the same cell line, this assay uses a High Content Imaging platform (Operetta, Perkin Elmer) to quantify the percentage of cells infected with Wolbachia following treatment. Using the methods described by Clare et al.  ADDIN EN.CITE (37), selected compounds were incubated with cells in a dose range from 5 µM to 19.5 nM in order to generate dose response curves and EC50 values. 

Chemoinformatics





Fig. S1: Box plots of the molecular properties of the 10,000 compounds screened and whether they were validated hits (>= 1 log drop). The bottom line of the box represents the lower quartile, the bold horizontal line indicates the median and * the mean, with the upper line of the box indicating the upper quartile. The horizontal lines at the ends of the dotted lines indicate the range of 1.5 of the interquartile range with data points outside this indicated by crosses. The width of the box is proportional to the number of molecules in the group (9950 and 50 respectively).
Table S1: Properties assessed to identify chemotypes for medicinal chemistry optimization
Scheme S1: Synthetic route for AWB124
Scheme S2: Synthetic route for AWG117
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H2: Figure Legends and Tables

Fig. 1: Primary screening workflow. The graphics and text demonstrate a typical screening run involving a batch of four compound plates (216 compounds), each plate represented by one color. Compounds were used in triplicate, as well as vehicle (dimethyl sulfoxide, DMSO) and doxycycline controls (shown as hatched areas). Following a nine day incubation, plates were scored for cytotoxicity using microscopy followed by cell lysis and DNA extraction. qPCR targeting the 16S rRNA gene of Wolbachia was conducted and data was subjected to quality control using Z′ statistical analysis. Wolbachia 16S log reductions (‘log drop’) were calculated per compound using in plate DMSO controls and those that were considered hits moved into confirmation screening. A more detailed description of this workflow is presented in Supplementary Materials and Methods.

Fig. 2: Screening cascade from primary screening to identification of lead series. Circles show numbers of compounds resulting from each step in the pipeline (shown in boxes).

Fig. 3: Chemical space depiction of the 50 validated hits. The first two principle components (PC1 and PC2) together account for 36.9% of the overall variance of the chemistry of these 50 compounds using molecular fingerprints (PathFp). The six distinct chemotypes show clustering in chemical space. The size of each data point is proportional to the total sore for that compound (maximum score 30).





Table 1: Cluster analysis of the 50 hits together with the core structures of the six clusters identified












Table 2: Measured EC50 value and DMPK properties for representatives from six identified hit clusters
Representative structure						
BioFocus code	790_4020_0354	729_2047_0052_ 0263	853_6001_0174	310_5632_5837_ 8158_0236	809_2679_5837_0109	894_7990_4021
Chemical Class/ Series Number	Thienopyrimidine (1)	Imidazo[4,5-c]pyridine (2)	Oxazepinone (3)	Imidazo[1,2-a]pyridine (4)	Pyrrolopyridine (5)	Oxazole imidazolidinone (6)
M. W. (g/mol)	358.5	292.4	407.5	448.5	347.4	458.4
EC50 ± s.d. (nM)	328 ± 55	847 ± 12	670 ± 9	112 ± 19	353 ± 77	5681 ± 756
LogD7.4	3.7	4.1	2.8	4.1	3.2	3.9
Solubility (µM)*	113	83	2	11	408	4
Measured Human* microsome clearance(µl/min/mg)	112	17.5	98	300	61	90
Rat hepatocytes clearance*(µl/min/1X106 cells)	300	21	102	300	21	109
Selection Score†	27	24	26	26	25	24
*Acceptable and desired ranges of measured parameters: EC50: <1,000 nM acceptable, <100 nM desired; LogD7.4: <5 acceptable, <3 desired; Aq. solubility: >20 µM acceptable, >50 µM desired; human microsome and rat hepatocytes clearance: <70 µl min-1 mg-1 and <70 µl min-11X106 cells -1 acceptable, <20 µl min-1 mg-1 and <20 µl min-11X106 cells -1 desired.
† Note that selection score was based solely on potency, logP, number of compounds in cluster and molecular weight as discussed in text.
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